/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
5G IoT Market Worth $6.3 Billion by 2025 – Exclusive Report by MarketsandMarkets™
According to a new market research report “5G IoT Market by Connection, Radio Technology (5G NR Standalone and 5G NR Non-Standalone Architecture), Range (Short- and Wide-Range IoT Devices), Vertical (Manufacturing, Energy & Utilities, Healthcare, Government), and Region – Global Forecast to 2025″, published by MarketsandMarkets, the 5G IoT Market size is expected to grow from USD 0.7 billion in 2020 to USD 6.3 billion by 2025, at a Compound Annual Growth Rate (CAGR) of 55.4% during the forecast period.
The adoption rate of 5G connectivity in IoT devices is expected to grow owing to the increase in demand for connected IoT devices.
Browse in-depth TOC on “5G IoT Market“
39 – Tables
32 – Figures
100 – Pages
Among radio technologies, the 5G NR standalone architecture segment to grow at the highest CAGR during the forecast period
5G NR standalone architecture is a completely new radio network. It mainly comprises 5G RAN and 5G core networks. 5G NR standalone solutions are expected to be more effective than 5G NR non-standalone solutions. The 5G NR standalone architecture is estimated to show the highest CAGR and expected to witness strong growth characteristics in the coming years.
Among range, the short-range IoT devices segment is expected to grow rapidly and hold the largest market size during the forecast period
Short-range IoT devices have a shorter coverage area as compared to wide-range IoT devices. Short-range IoT devices range from 0 to 150 meters. Connectivity plays an important role in the IoT ecosystem. Currently, various range of connectivity options is available for IoT stakeholders. Cellular IoT technologies, such as Cat-M1 and NB-IoT, are gaining traction across industry verticals. Short-range IoT devices need low power and minimal security for surviving in the IoT ecosystem.
Speak to Analyst:
https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=164027845
North America is expected to account for the largest market size during the forecast period
North America is the largest contributor to the 5G IoT Market. The top countries contributing to the 5G IoT Market in this region include the US and Canada. The leading telecom operators, such as AT&T, Verizon, Sprint, Rogers, Bell, and Telus, have announced the deployment of 5G networks. Verizon has planned to roll out 5G services across 30 cities in the US by the end of 2020. T-Mobile has also announced to launch 5G services in 30 cities. AT&T has already introduced 5G services in 12 cities. These service providers have collaborated with network enablers such as Ericsson, Nokia, and Samsung, to launch 5G services across the US.
In the 5G IoT Market, the key and emerging market players include Ericsson (Sweden), Nokia (Finland), Huawei (China), AT&T (US), Verizon (US), Sprint (US), Telefónica (Spain), BT Group (UK), Vodafone (UK), Telstra (Australia), Etisalat (UAE), Telus (Canada), Bell Canada (Canada), Singtel (Singapore), and Rogers (Canada). These players have adopted various strategies to grow in the global 5G IoT Market.
Browse Adjacent Markets: Mobility and Telecom Market Research Reports & Consulting
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Cannabis
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
transfer
IMC to transfer its Oranim Pharmacy shares back to the seller
TORONTO and GLIL YAM, Israel, April 16, 2024 /PRNewswire/ — IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the “Company” or “IMC“), a leading medical cannabis company with operations in Israel and Germany, is announcing that, further to the news release dated January 12, 2024, the Company has decided not to make remaining installment payments installments (i.e. NIS 5,873K including interest or 2,154K CAD) by IMC Holdings Ltd., and as such will transfer the 51% shares held by IMC Holdings Ltd back to the seller.
“With the April 1st cannabis legalization in Germany, we are focusing our resources on the German market, where we expect to see the biggest growth potential,” said Oren Shuster, CEO of IMC. “With both of our core markets, Germany and Israel, currently undergoing rapid evolution, we need to assure that we allocate our resources to the growth opportunities where we expect the best return on investment.”
About IM Cannabis Corp.
IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has recently exited operations in Canada to pivot its focus and resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.
The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC’s products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. Until recently, the Company also actively operated in Canada through Trichome Financial Corp and its wholly owned subsidiaries, where it cultivated, processed, packaged, and sold premium and ultra-premium cannabis at its own facilities under the WAGNERS and Highland Grow brands for the adult-use market in Canada. The Company has exited operations in Canada and considers these operations discontinued.
Disclaimer for Forward-Looking Statements
This press release contains forward-looking information or forward-looking statements under applicable Canadian and U.S. securities laws (collectively, “forward-looking statements”). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, the occurrence of growth opportunities and the likelihood of growth potential.
Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the development and introduction of new products; continuing demand for medical and adult-use recreational cannabis in the markets in which the Company operates; the Company’s ability to reach patients through both e-commerce and brick and mortar retail operations; the Company’s ability to maintain and renew or obtain required licenses; the effectiveness of its products for medical cannabis patients and recreational consumers; and the Company’s ability to market its brands and services successfully to its anticipated customers and medical cannabis patients.
The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward looking statements due to a number of factors and risks. These include: any failure of the Company to maintain “de facto” control over Focus Medical in accordance with IFRS 10; the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the effect of the reform on the Company; the Company’s ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and Focus Medical (collectively, the “Group”) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt and war, conflict and civil unrest in Eastern Europe and the Middle East
Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made.
The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
Company Contacts:
Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]
Oren Shuster, Chief Executive Officer
IM Cannabis Corp.
[email protected]
Logo – https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/imc-to-transfer-its-oranim-pharmacy-shares-back-to-the-seller-302117984.html
Cannabis
Right on Brands Announces Major Product Line Expansion via HONEY® Brands
-
Avant2 weeks ago
Avant and IMC Execute BLK MKT™ Trademark Licensing Agreement for the German Medical Cannabis Market
-
StickIt2 weeks ago
StickIt Technologies Inc. Announces Year-End 2023 Financial Results
-
Cannabis1 week ago
Hemp, Inc. Welcomes USDA Approval of GMO Hemp Strain – A Step Forward in Cannabis Biotechnology
-
Cannabis1 week ago
Right On Brands, Inc. Continues Rollout, Announces 13th Store Opening
-
Cannabis1 week ago
IM Cannabis and Flora Growth Partner to Bring Vessel Cannabis Accessories to the Israeli Market
-
Cannabis1 week ago
Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study
-
Cannabis1 week ago
Tilray Brands, Inc. Reports Q3 Fiscal 2024 Financial Results
-
Cannabis1 week ago
Geopulse Exploration, Inc. Acquires 50% of ATC Services